Please select the option that best describes you:

Would you consider transition to cabotegravir/rilpivirine injectable regimen in a patient living with HIV who is well suppressed on BIC/FTC/TAF since initial diagnosis in Colombia in 2022 at which time her viral load was in the 400s precluding genotypic resistance testing?

Answer from: at Academic Institution

The clinical scenario as presented is somewhat ambiguous. If the patient is described as “well suppressed” on bictegravir/emtricitabine/tenofovir alafenamide, this typically implies consistent HIV RNA <200 copies/mL. A persistent viral load in the 400s, however, would s...

Please select the option that best describes you:

Would you consider transition to cabotegravir/rilpivirine injectable regimen in a patient living with HIV who is well suppressed on BIC/FTC/TAF since initial diagnosis in Colombia in 2022 at which time her viral load was in the 400s precluding genotypic resistance testing?

Related Questions